Research programme: extracorporeal antibody therapies - Premier Biomedical

Drug Profile

Research programme: extracorporeal antibody therapies - Premier Biomedical

Alternative Names: Sequential dialysis therapy - Premier Biomedical

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Premier Biomedical
  • Developer Premier Biomedical; University of Texas at El Paso; William Beaumont Army Medical Center
  • Class Monoclonal antibodies
  • Mechanism of Action Cytokine inhibitors; Glutamate modulators; Immunomodulators; Neurotransmitter inhibitors; Neurotransmitter modulators; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer metastases
  • Research Amyotrophic lateral sclerosis; Cockayne syndrome; Neurofibromatoses
  • No development reported Alzheimer's disease; Brain injuries; Major depressive disorder; Retinitis pigmentosa

Most Recent Events

  • 06 Dec 2016 Premier Biomedicals files for patent protection for CTLA-4 blockade in conjunction with metronomic chemotherapy
  • 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA (Extracorporeal)
  • 16 Jul 2016 No recent reports of development identified for research development in Brain injuries in USA (Extracorporeal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top